Our Pricing

NHS Weight Loss Injection Treatment Online

Published on: June 03, 2026

Accessing NHS weight loss injection treatment online through a registered UK pharmacy offers a convenient alternative to lengthy GP waiting lists. At Cured Pharmacy, our UK-registered clinical team provides the same prescription-only weight loss injections recommended by NICE guidelines, with transparent pricing and discreet home delivery following a free online consultation.

How NHS-Recommended Weight Loss Injections Work

The weight loss injections available through our service mirror those prescribed through the NHS Weight Management Programme. These medications—tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda)—belong to a class called GLP-1 receptor agonists, which work by mimicking natural gut hormones that regulate appetite and blood sugar [1].

GLP-1 medications slow gastric emptying, reduce hunger signals to the brain, and improve insulin sensitivity. In the landmark STEP trials, participants using semaglutide achieved an average 14.9% body weight reduction over 68 weeks when combined with lifestyle interventions [2]. Tirzepatide, a dual GIP/GLP-1 agonist, demonstrated even greater efficacy in the SURMOUNT-1 trial, with patients losing up to 22.5% of their initial body weight on the highest dose [3].

These medications are licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions such as type 2 diabetes or hypertension. All prescriptions require clinical assessment by a UK-registered prescriber to ensure suitability and safety.

Comparing Weight Loss Injection Options Available Online

Choosing between available weight loss injections depends on your medical history, weight loss goals, and tolerance for side effects. Our UK prescribers assess these factors during your online consultation to recommend the most appropriate treatment.

Mounjaro (Tirzepatide): Dual-Action Treatment

Mounjaro represents the newest generation of weight loss injections, activating both GIP and GLP-1 receptors simultaneously. This dual mechanism produces superior weight loss outcomes compared to single-pathway treatments in head-to-head clinical trials [3]. Administered once weekly via a pre-filled KwikPen, Mounjaro requires dose escalation over several months to minimise gastrointestinal side effects. Starting from £135.00 at Cured Pharmacy, treatment cost varies depending on your prescribed maintenance dose.

Wegovy and Saxenda: Established Semaglutide and Liraglutide Options

Saxenda (liraglutide) was the first GLP-1 medication licensed specifically for weight management in the UK. Unlike Mounjaro and Wegovy, Saxenda requires daily injections, which some patients find less convenient but others prefer for more consistent appetite control throughout the day. Clinical trials showed an average weight loss of 8% over 56 weeks [4]. Saxenda may be particularly suitable for patients who have previously used liraglutide for diabetes management or those who prefer daily dosing.

Both medications require prescription from a UK-registered prescriber following clinical assessment. Our online consultation process takes under three minutes and reviews your medical history, current medications, and weight loss goals to determine the most appropriate treatment option.

Wegovy (Semaglutide): Once-Weekly Convenience

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied in the STEP clinical trial programme. Across four major trials involving over 4,500 participants, Wegovy consistently delivered significant weight loss when combined with reduced-calorie diet and increased physical activity [2]. The once-weekly injection schedule offers convenience, and the medication is generally well-tolerated with dose escalation protocols that reduce side effect severity.

The Online Consultation Process for NHS Weight Loss Injection Treatment

Accessing NHS weight loss injection treatment online through Cured Pharmacy follows the same clinical standards as in-person GP consultations. Our process begins with a comprehensive medical questionnaire that covers your weight history, previous weight loss attempts, current medications, and any relevant health conditions.

A UK-registered prescriber from our clinical team—overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073)—reviews your assessment within hours. They evaluate whether you meet NICE criteria for weight loss medication, check for contraindications, and determine the appropriate starting dose. If approved, your prescription is sent electronically to our GPhC-registered pharmacy (9012511) for dispensing.

Patients receive ongoing support throughout treatment. Follow-up consultations monitor your progress, adjust dosing as needed, and address any side effects. This mirrors the structured approach recommended by NICE guidelines for weight management services, ensuring you receive the same level of clinical oversight as NHS-provided programmes.

Eligibility Criteria and Clinical Considerations

Certain medical conditions may preclude use of weight loss injections. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and diabetic retinopathy requiring active treatment. Pregnancy and breastfeeding are also contraindications, and women of childbearing age should use effective contraception during treatment [1][3].

Your online consultation will screen for these factors. Our prescribers may request additional information or recommend alternative treatments if weight loss injections are not suitable. This thorough assessment process protects patient safety whilst providing convenient access to effective weight management medications.

Who Can Access Weight Loss Injection Treatment

NICE guidelines recommend GLP-1 medications for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [5]. These criteria align with NHS prescribing protocols and ensure medications are used appropriately for patients who will benefit most.

Managing Side Effects and Optimising Treatment Outcomes

Practical strategies can reduce side effect severity. Eating smaller, more frequent meals rather than large portions helps manage nausea. Avoiding high-fat foods, staying well-hydrated, and not lying down immediately after eating also improve tolerance. If side effects persist or become severe, your prescriber can slow dose escalation or adjust your treatment plan.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other diabetes medications). Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Our clinical team provides detailed safety information with every prescription and remains available for questions throughout your treatment journey.

Common Side Effects and Mitigation Strategies

Gastrointestinal side effects—nausea, vomiting, diarrhoea, and constipation—are the most frequently reported adverse events with GLP-1 medications, affecting 30-50% of patients in clinical trials [2][3]. These symptoms typically occur during dose escalation and diminish over several weeks as your body adapts. Starting at a low dose and gradually increasing helps minimise discomfort.

Scientific References

1. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment protocols and lifestyle modifications.